The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Russell Z. Szmulewitz and Daniel Shevrin.
Connection Strength

0.296
  1. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
    View in: PubMed
    Score: 0.209
  2. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
    View in: PubMed
    Score: 0.062
  3. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.